公开(公告)号：US20240102978A1

公开(公告)日：2024-03-28

申请号：US17996103

申请日：2021-04-12

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Carlo Giannelli ,  Francesca Micoli ,  Maria Michelina Raso

IPC: G01N30/88 ,  G01N1/40 ,  G01N30/06

CPC classification number: G01N30/88 ,  G01N1/4044 ,  G01N30/06 ,  G01N2001/4016 ,  G01N2030/8836 ,  G01N2333/255

Abstract: The present invention provides a method for measuring the concentration and/or amount of one or more polysaccharide in a test sample comprising or consisting of the steps of (a) acid hydrolysis of the test sample with hydrochloric acid and trifluoroaceticacid; (b) chromatographic separation of the hydrolysed test sample of step (a); and (c) determining the concentration and/or amount of the one or more polysaccharide based on the data generated in step (b), together with processed test samples and kit for use of the same.

公开(公告)号：US20240091345A1

公开(公告)日：2024-03-21

申请号：US18262073

申请日：2022-01-18

Applicant: GlaxoSmithKline Biologicals SA

Inventor： Johann MOLS ,  Marie TOUSSAINT

IPC: A61K39/245 ,  A61P31/22

CPC classification number: A61K39/245 ,  A61P31/22 ,  A61K2039/53

Abstract: The present invention relates to a nucleic acid encoding a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a nucleic acid encoding a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.

公开(公告)号：US11905514B2

公开(公告)日：2024-02-20

申请号：US18080164

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

公开(公告)号：US11891608B2

公开(公告)日：2024-02-06

申请号：US18080150

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus, the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

公开(公告)号：US11865080B2

公开(公告)日：2024-01-09

申请号：US18065069

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall ,  Katrin Ramsauer ,  Gillis Otten ,  Christian Walter Mandl

IPC: A61K39/00 ,  A61K39/12 ,  A61K31/7088

CPC classification number: A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2770/36143

Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.

公开(公告)号：US20230414736A1

公开(公告)日：2023-12-28

申请号：US18329701

申请日：2023-06-06

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Alessia BIOLCHI ,  Brunella BRUNELLI ,  Marzia GIULIANI ,  Vega MASIGNANI

IPC: A61K39/095 ,  C07K14/22 ,  A61K39/385

CPC classification number: A61K39/095 ,  C07K14/22 ,  A61K39/385 ,  A61K2039/55505

Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.

公开(公告)号：US11851660B2

公开(公告)日：2023-12-26

申请号：US18065267

申请日：2022-12-13

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: C12N15/117 ,  C12N15/86 ,  A61K39/155 ,  A61K39/39 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61K48/00 ,  A61K39/00

CPC classification number: C12N15/117 ,  A61K39/12 ,  A61K39/155 ,  A61K39/39 ,  A61K48/0041 ,  A61K48/0083 ,  A61P31/12 ,  A61P37/04 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55566 ,  C12N2760/18534 ,  C12N2770/36143 ,  C12N2820/60

Abstract: RNA encoding an immunogen is delivered to a large mammal at a dose of between 2 μg and 100 μg. Thus the invention provides a method of raising an immune response in a large mammal, comprising administering to the mammal a dose of between 2 μg and 100 μg of immunogen-encoding RNA. Similarly, RNA encoding an immunogen can be delivered to a large mammal at a dose of 3 ng/kg to 150 ng/kg. The delivered RNA can elicit an immune response in the large mammal.

公开(公告)号：US20230357369A1

公开(公告)日：2023-11-09

申请号：US18323177

申请日：2023-05-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Philip R. DORMITZER

IPC: A61K39/155 ,  A61K39/12 ,  C07K14/005 ,  C07K16/10

CPC classification number: C07K16/1027 ,  A61K39/12 ,  A61K39/155 ,  C07K14/005 ,  A61K2039/5252

Abstract: The present invention relates to immunogenic compositions comprising RSV F protein, methods for preparing compositions that contain RSV F protein ecto-domain polypeptides, and to certain engineered RSV F proteins and nucleic acids that encode the engineered RSV F proteins. Compositions prepared using the methods can contain RSV F protein ecto-domain polypeptides in a predominant or single desired form and conformation. The invention also relates to methods for inducing an immune response to RSV F.

公开(公告)号：US20230346905A1

公开(公告)日：2023-11-02

申请号：US18042355

申请日：2021-08-23

Applicant: GlaxosmithKline Biologicals SA

Inventor： Roberto ADAMO ,  Maria Rosaria ROMANO ,  Marta TONTINI

IPC: A61K39/095 ,  A61P31/04

CPC classification number: A61K39/095 ,  A61P31/04 ,  A61K2039/70

Abstract: The inventors have identified a combined vaccine for immunisation against bacterial meningitis caused by multiple pathogens.

公开(公告)号：US11766401B2

公开(公告)日：2023-09-26

申请号：US17560059

申请日：2021-12-22

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrew Geall

IPC: A61K48/00 ,  A61K9/127 ,  A61K39/12 ,  C12N15/86 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/39

CPC classification number: A61K9/127 ,  A61K9/1272 ,  A61K31/7088 ,  A61K39/00 ,  A61K39/12 ,  C12N15/86 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55555 ,  C12N2710/16134 ,  C12N2760/18534 ,  C12N2770/36134

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.